SCHEMBL19631119

SCHEMBL19631119

CCCN(CCN(O)CO)S(=O)(=O)c1cccc(C(=O)Nc2ccc(F)c(Cl)c2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.57
▸ TSHR P16473 3/20 0.57
▸ ALDH1A1 P00352 3/20 0.57
▸ GAA P10253 1/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ NPSR1 Q6W5P4 1/20 0.57
▸ CA12 O43570 5/20 0.55
▸ CA9 Q16790 5/20 0.55
▸ CA1 P00915 4/20 0.55
▸ LMNA P02545 5/20 0.49
▸ SMN1; SMN2 Q16637 4/20 0.49
▸ RAB9A P51151 3/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ NPC1 O15118 2/20 0.47
▸ POLB P06746 2/20 0.47
▸ HTT P42858 1/20 0.47
▸ HTR2B P41595 1/20 0.44
▸ SIRT2 Q8IXJ6 3/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15276902 0.84 SMN1; SMN2 (0.59) MAPTTSHRALDH1A1GAAMAPK1
SCHEMBL15276896 0.80 LMNA (0.55) MAPTTSHRALDH1A1LMNASMN1; SMN2
SCHEMBL21844936 0.79 ALDH1A1 (0.63) MAPTTSHRALDH1A1GAAMAPK1
SCHEMBL16770389 0.78 ALDH1A1 (0.55) MAPTTSHRALDH1A1GAAMAPK1
SCHEMBL15276919 0.77 MAPT (0.53) MAPTALDH1A1LMNASMN1; SMN2RAB9A
SCHEMBL15838864 0.75 MAPT (0.67) MAPTTSHRALDH1A1GAAMAPK1
SCHEMBL15276909 0.75 RAB9A (0.50) MAPTTSHRALDH1A1GAAMAPK1
SCHEMBL15276917 0.75 LMNA (0.52) MAPTTSHRALDH1A1MAPK1LMNA
SCHEMBL15076671 0.75 RAB9A (0.55) MAPTTSHRALDH1A1LMNASMN1; SMN2
SCHEMBL15838841 0.74 ALDH1A1 (0.66) MAPTTSHRALDH1A1GAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170334882-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC 2017-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334882-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 MAPT 4607/4885TSHR 4028/4885ALDH1A1 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback